GlycoNex Inc. and Nippon Kayaku Enter Collaboration to Advance Next-Gen ADC Candidate GNX201-ADC March 24, 2026
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Gen T-Cell Engager Therapies March 24, 2026
Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Ph 1b/2a Agent and Announces First Close of Seed Financing March 10, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program March 10, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. March 10, 2026
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine March 10, 2026
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8M March 10, 2026
Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics March 10, 2026
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission March 10, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
Astellas and Vir Biotechnology to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer March 3, 2026
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform March 3, 2026
AIM ImmunoTech Signs Agreement for Planning of Proposed Ph 3 Trial of Ampligen in Late-Stage Pancreatic Cancer March 3, 2026
Synthekine and Merck to Evaluate STK-012, Keytruda, and Chemo in Ph 2 Trial in 1L PD-L1-Neg Nonsquamous NSCLC March 3, 2026
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a Ph 1 ready Molecular Glue for GIST February 25, 2026
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics February 25, 2026
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors February 25, 2026
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200M Concurrent Private Placement February 25, 2026
SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery February 25, 2026
